Neurological deficits caused by tissue hypoxia in neuroinflammatory disease

Annals of Neurology

Volumn 74, Issue 6, 2013, Pages 815-825

  Davies, Andrew L ^a   Desai, Roshni A ^a   Bloomfield, Peter S ^a   McIntosh, Peter R ^a   Chapple, Katie J ^b   Linington, Christopher ^b   Fairless, Richard ^c   Diem, Ricarda ^c   Kasti, Marianne ^a   Murphy, Michael P ^d   Smith, Kenneth J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; FREUND ADJUVANT; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INDUCIBLE NITRIC OXIDE SYNTHASE; MITOQ; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; N [3 (AMINOMETHYL)BENZYL]ACETAMIDINE; OXYGEN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL DIAMETER; BRAIN MITOCHONDRION; CELL LOSS; CONTROLLED STUDY; ENZYME INHIBITION; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; GRAY MATTER; HYPOXEMIA; MICROVASCULATURE; MULTIPLE SCLEROSIS; NONHUMAN; OXYGEN TENSION; OXYGEN THERAPY; PHYSICAL SENSITIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RELAPSE; SPINAL CORD ISCHEMIA; WHITE MATTER;

AMIDINES; ANIMALS; ANOXIA; BENZYLAMINES; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENZYME INHIBITORS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INFLAMMATION; MICRONUTRIENTS; ORGANOPHOSPHORUS COMPOUNDS; OXYGEN; RATS; RECOVERY OF FUNCTION; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; SPINAL CORD DISEASES; UBIQUINONE;

EID: 84892914956     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24006     Document Type: Article

References (55)

1. Moreau T, Coles A, Wing M, et al. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 1996; 119: 225-237.
2. Bitsch A, Wegener C, Da Costa C, et al. Lesion development in Marburg's type of acute multiple sclerosis: from inflammation to demyelination. Mult Scler 1999; 5: 138-146.
3. Redford EJ, Kapoor R, Smith KJ,. Nitric oxide donors reversibly block axonal conduction: demyelinated axons are especially susceptible. Brain 1997; 120: 2149-2157.
4. Aboul-Enein F, Lassmann H,. Mitochondrial damage and histotoxic hypoxia: a pathway of tissue injury in inflammatory brain disease? Acta Neuropathol 2005; 109: 49-55.
5. Aboul-Enein F, Rauschka H, Kornek B, et al. Preferential loss of myelin-associated glycoprotein reflects hypoxia-like white matter damage in stroke and inflammatory brain diseases. J Neuropathol Exp Neurol 2003; 62: 25-33.
6. Graumann U, Reynolds R, Steck AJ, et al. Molecular changes in normal appearing white matter in multiple sclerosis are characteristic of neuroprotective mechanisms against hypoxic insult. Brain Pathol 2003; 13: 554-573.
7. Zeis T, Probst A, Steck AJ, et al. Molecular changes in white matter adjacent to an active demyelinating lesion in early multiple sclerosis. Brain Pathol 2009; 19: 459-466.
8. Arteel GE, Thurman RG, Raleigh JA,. Reductive metabolism of the hypoxia marker pimonidazole is regulated by oxygen tension independent of the pyridine nucleotide redox state. Eur J Biochem 1998; 253: 743-750.
9. Arteel GE, Thurman RG, Yates JM, et al. Evidence that hypoxia markers detect oxygen gradients in liver: pimonidazole and retrograde perfusion of rat liver. Br J Cancer 1995; 72: 889-895.
10. Liu S, Timmins GS, Shi H, et al. Application of in vivo EPR in brain research: monitoring tissue oxygenation, blood flow, and oxidative stress. NMR Biomed 2004; 17: 327-334.
11. Smith RA, Murphy MP,. Animal and human studies with the mitochondria-targeted antioxidant MitoQ. Ann N Y Acad Sci 2010; 1201: 96-103.
12. Storch MK, Stefferl A, Brehm U, et al. Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol 1998; 8: 681-694.
13. Brown GC, Neher JJ,. Inflammatory neurodegeneration and mechanisms of microglial killing of neurons. Mol Neurobiol 2010; 41: 242-247.
14. Babior BM,. The respiratory burst of phagocytes. J Clin Invest 1984; 73: 599-601.
15. Stuehr D, Pou S, Rosen GM,. Oxygen reduction by nitric-oxide synthases. J Biol Chem 2001; 276: 14533-14536.
16. Robinson MA, Baumgardner JE, Otto CM,. Oxygen-dependent regulation of nitric oxide production by inducible nitric oxide synthase. Free Radic Biol Med 2011; 51: 1952-1965.
17. Bulua AC, Simon A, Maddipati R, et al. Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS). J Exp Med 2011; 208: 519-533.
18. Haufschild T, Shaw SG, Kesselring J, et al. Increased endothelin-1 plasma levels in patients with multiple sclerosis. J Neuroophthalmol 2001; 21: 37-38.
19. Pache M, Kaiser HJ, Akhalbedashvili N, et al. Extraocular blood flow and endothelin-1 plasma levels in patients with multiple sclerosis. Eur Neurol 2003; 49: 164-168.
20. Dake MD,. Chronic cerebrospinal venous insufficiency and multiple sclerosis: history and background. Tech Vasc Interv Radiol 2012; 15: 94-100.
21. Yu XX, Barger JL, Boyer BB, et al. Impact of endotoxin on UCP homolog mRNA abundance, thermoregulation, and mitochondrial proton leak kinetics. Am J Physiol Endocrinol Metab 2000; 279: E433-E446.
22. Smith KJ, Bostock H, Hall SM,. Saltatory conduction precedes remyelination in axons demyelinated with lysophosphatidyl choline. J Neurol Sci 1982; 54: 13-31.
23. Bostock H, Sears TA,. Continuous conduction in demyelinated mammalian nerve fibers. Nature 1976; 263: 786-787.
24. Leone AM, Palmer RM, Knowles RG, et al. Constitutive and inducible nitric oxide synthases incorporate molecular oxygen into both nitric oxide and citrulline. J Biol Chem 1991; 266: 23790-23795.
25. Ames A III, Li YY, Heher EC, et al. Energy metabolism of rabbit retina as related to function: high cost of Na+ transport. J Neurosci 1992; 12: 840-853.
26. Astrup J,. Energy-requiring cell functions in the ischemic brain. Their critical supply and possible inhibition in protective therapy. J Neurosurg 1982; 56: 482-497.
27. Simmons RD, Bernard CC, de Kerlero de RN, et al. Criteria for an adequate explanation of typical clinical signs of EAE in rodents. Prog Clin Biol Res 1984; 146: 23-29.
28. Brown GC,. Nitric oxide and neuronal death. Nitric Oxide 2010; 23: 153-165.
29. Zeis T, Graumann U, Reynolds R, et al. Normal-appearing white matter in multiple sclerosis is in a subtle balance between inflammation and neuroprotection. Brain 2008; 131: 288-303.
30. Stadelmann C, Ludwin S, Tabira T, et al. Tissue preconditioning may explain concentric lesions in Balo's type of multiple sclerosis. Brain 2005; 128: 979-987.
31. Lassmann H, Reindl M, Rauschka H, et al. A new paraclinical CSF marker for hypoxia-like tissue damage in multiple sclerosis lesions. Brain 2003; 126: 1347-1357.
32. Mhaille AN, McQuaid S, Windebank A, et al. Increased expression of endoplasmic reticulum stress-related signaling pathway molecules in multiple sclerosis lesions. J Neuropathol Exp Neurol 2008; 67: 200-211.
33. McMahon JM, McQuaid S, Reynolds R, et al. Increased expression of ER stress- and hypoxia-associated molecules in grey matter lesions in multiple sclerosis. Mult Scler 2012; 18: 1437-1447.
34. Regenold WT, Phatak P, Makley MJ, et al. Cerebrospinal fluid evidence of increased extra-mitochondrial glucose metabolism implicates mitochondrial dysfunction in multiple sclerosis disease progression. J Neurol Sci 2008; 275: 106-112.
35. Davie CA, Hawkins CP, Barker GJ, et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 1994; 117: 49-58.
36. Lassmann H, van Horssen J,. The molecular basis of neurodegeneration in multiple sclerosis. FEBS Lett 2011; 585: 3715-3723.
37. Lassmann H, Wekerle H,. The pathology of multiple sclerosis. In:, Compston A, Confavreux C, Lassmann H, et al, eds. McAlpine's multiple sclerosis. 4th ed. London, UK: Churchill Livingstone, 2006: 557-599.
38. van Horssen J, Witte ME, Schreibelt G, et al. Radical changes in multiple sclerosis pathogenesis. Biochim Biophys Acta 2011; 1812: 141-150.
39. Smith KJ, Lassmann H,. The role of nitric oxide in multiple sclerosis. Lancet Neurol 2002; 1: 232-241.
40. Jekabsone A, Neher JJ, Borutaite V, et al. Nitric oxide from neuronal nitric oxide synthase sensitises neurons to hypoxia-induced death via competitive inhibition of cytochrome oxidase. J Neurochem 2007; 103: 346-356.
41. Mander P, Borutaite V, Moncada S, et al. Nitric oxide from inflammatory-activated glia synergizes with hypoxia to induce neuronal death. J Neurosci Res 2005; 79: 208-215.
42. Hagen T, Taylor CT, Lam F, et al. Redistribution of intracellular oxygen in hypoxia by nitric oxide: effect on HIF1alpha. Science 2003; 302: 1975-1978.
43. Xu K, LaManna JC,. Chronic hypoxia and the cerebral circulation. J Appl Physiol 2006; 100: 725-730.
44. Holley JE, Newcombe J, Whatmore JL, et al. Increased blood vessel density and endothelial cell proliferation in multiple sclerosis cerebral white matter. Neurosci Lett 2010; 470: 65-70.
45. Seabrook TJ, Littlewood-Evans A, Brinkmann V, et al. Angiogenesis is present in experimental autoimmune encephalomyelitis and pro-angiogenic factors are increased in multiple sclerosis lesions. J Neuroinflammation 2010; 7: 95.
46. Nathoo N, Agrawal S, Wu Y, et al. Susceptibility-weighted imaging in the experimental autoimmune encephalomyelitis model of multiple sclerosis indicates elevated deoxyhemoglobin, iron deposition and demyelination. Mult Scler 2013; 19: 721-731.
47. Jonez HD,. Multiple sclerosis; treatment with histamine and d-tubocurarine. Ann Allergy 1948; 6: 550-563.
48. Brickner RM,. Phenomenon of relief by flush in multiple sclerosis. AMA Arch Neurol Psychiatry 1955; 73: 232-240.
49. Horton BT,. The clinical use of histamine. Postgrad Med 1951; 9: 1-10.
50. Brickner RM,. Pharmacological reduction of abnormality in multiple sclerosis within minutes: a statistical study. J Nerv Ment Dis 1958; 127: 308-322.
51. Correia SC, Moreira PI,. Hypoxia-inducible factor 1: a new hope to counteract neurodegeneration? J Neurochem 2010; 112: 1-12.
52. Fischer BH, Marks M, Reich T,. Hyperbaric-oxygen treatment of multiple sclerosis. N Engl J Med 1983; 308: 181-186.
53. Bennett M, Heard R,. Hyperbaric oxygen therapy for multiple sclerosis. CNS Neurosci Ther 2010; 16: 115-124.
54. Prime TA, Blaikie FH, Evans C, et al. A mitochondria-targeted S-nitrosothiol modulates respiration, nitrosates thiols, and protects against ischemia-reperfusion injury. Proc Natl Acad Sci U S A 2009; 106: 10764-10769.
55. Amor S, Puentes F, Baker D, et al. Inflammation in neurodegenerative diseases. Immunology 2010; 129: 154-169.